Drug evaluation: DNA/MVA prime-boost HIV vaccine.
Oxford University and Nairobi University are jointly developing a HIVA.DNA/modified vaccinia Ankara (MVA) prime-boost vaccine for the potential prevention of infection with HIV subtype A. The vaccination strategy consists of priming with a DNA vaccine made from HIV-1 clade A gag p24/p17 consensus sequence (pTHr.HIVA) then boosting with a MVA virus expressing HIVA (MVA.HIVA). Phase II clinical trials of the vaccine are underway in Kenya and the UK.
Kent
Stephen
S
University of Melbourne, Department of Microbiology and Immunology, Melbourne, Victoria 3010, Australia. skent@unimelb.edu.au
De Rose
Robert
R
Rollman
Erik
E
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007630:Kenya; D006113:United Kingdom; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology
D016915:AIDS Vaccines; D019444:Vaccines, DNA